Company: WENNU
Filing Date: 2025-04-30
Form Type: S-1
Source: 0001213900-25-037753
Chunk: 163

Company: WEN Acquisition Corp
Filing Date: 2025-04-30
Form: S-1
Chunk 163
---
. Patel served as Chief Operating Officer, to FTAC Olympus Acquisition Corp. (NASDAQ: FTOC) (“FTOC”). FTOC, after its initial public offering of $755 million in August 2020, consummated its initial business combination with Payoneer Global Inc. (NASDAQ: PAYO) in June 2021. In connection with the business combination, approximately 23.9% of FTAC Olympus’ public shares were redeemed. PIPE investors committed to purchase an aggregate of $300.0million in common stock, at a price of $10.00 per share. Payoneer’s closing price on April25, 2025 was $6.97 per share. • Locust Walk Acquisition Corp.: Mr. Gilbert and Mr. Patel served as advisors to Locust Walk Acquisition Corp. (NASDAQ: LWAC) which merged with eFFECTOR therapeutics (NASDAQ: EFTR) in August 2021 (in which approximately 97.0% of LWAC’s public shares were redeemed). PIPE investors committed to purchase an aggregate of $60.7million in common stock, at a price of $10.00 per share. eFFECTOR therapeutics effected a wind down in June 2024 and no longer trades on an exchange. • Phoenix Biotech Acquisition Corp.: Mr.Gilbert and Mr.Patel served as advisors to Phoenix Biotech Acquisition Corp. (NASDAQ: PBAX), which merged with CERo Therapeutics (Nasdaq: CERO) in February 2024 Phoenix Biotech Acquisition Corp. experienced redemptions of approximately 92.6% of its public shares in connection with an extension in December 2022, approximately 40.6% of the remaining public shares in connection with an extension in July 2023, approximately 1.5% of the remaining public shares in connection with an extension in January 2024 and approximately 89.1% of the remaining public shares in connection with the consummation of the business combination. PIPE Investors purchased, 12,580shares of Series A convertible preferred stock, warrants to purchase 125,000shares and warrants to purchase 2,000shares of Series A Preferred Stock, for aggregate cash proceeds to Phoenix Biotech Acquisition Corp. of approximately $9.4million. CERo Therapeutic’s closing price on April25, 2025 was $0.89 per share. • Newcourt Acquisition Corp.: Mr. Van de Vyver served as chief financial officer of, and